drugset
drugset / Trial / NCT01763333

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

NCT01763333 ↗

Phase 1 Completed 80 enrolled Boehringer Ingelheim
RandomizedSingle-groupSingle-blindTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of BI 1026706

Timeline

Start
2013-01-08
Primary completion
2013-09-04
Completion
2013-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1026706 Unknown — —

Indications

No indication recorded.